Anti-IL-23 monoclonal antibody - Merck

Drug Profile

Anti-IL-23 monoclonal antibody - Merck

Latest Information Update: 08 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 08 Aug 2011 No development reported - Phase-I for Inflammation in USA (Parenteral)
  • 04 Nov 2009 Schering-Plough combines with Merck & Co and retains the name Merck & Co
  • 01 Dec 2008 Phase-I clinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top